BC
SYRE icon

Bridgefront Capital’s Spyre Therapeutics SYRE Stock Holding History

Bridgefront Capital’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$318K Sell
3,577
-5,075
-59% -$370K 0.08% 359
2026
Q1 		$436K Buy
+8,652
New +$326K 0.11% 305

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Bridgefront Capital's SYRE Position: Q2 2026 in Review

Bridgefront Capital reduced its Spyre Therapeutics (SYRE) stake by 59% in Q2 2026, selling an estimated $370K and leaving 3,577 shares worth $318K. The position accounts for 0.08% of the portfolio, ranked #359.

Bridgefront Capital first reported a position in SYRE in Q1 2026 and has held it in 2 quarters since. The position peaked at $436K in Q1 2026. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Bridgefront Capital held 3,577 shares of Spyre Therapeutics worth $318K as of Q2 2026.
  • Bridgefront Capital sold 5,075 Spyre Therapeutics shares in Q2 2026, an estimated $370K.
  • Spyre Therapeutics made up 0.08% of Bridgefront Capital's portfolio in Q2 2026, its #359 holding.
  • Bridgefront Capital first reported a position in Spyre Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Bridgefront Capital's Spyre Therapeutics position peaked at $436K in Q1 2026.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.